Jazz Pharmaceuticals (JAZZ) R&D In Process (2016 - 2025)
Jazz Pharmaceuticals (JAZZ) has 9 years of R&D In Process data on record, last reported at $10.0 million in Q1 2024.
- For Q1 2024, R&D In Process rose 900.0% year-over-year to $10.0 million; the TTM value through Dec 2024 reached $10.0 million, down 58.33%, while the annual FY2025 figure was $947.9 million, 9378.62% up from the prior year.
- R&D In Process reached $10.0 million in Q1 2024 per JAZZ's latest filing, down from $18.0 million in the prior quarter.
- Across five years, R&D In Process topped out at $202.2 million in Q1 2020 and bottomed at $1.0 million in Q1 2023.
- Average R&D In Process over 4 years is $40.4 million, with a median of $14.0 million recorded in 2020.
- Peak YoY movement for R&D In Process: crashed 80.69% in 2020, then surged 900.0% in 2024.
- A 4-year view of R&D In Process shows it stood at $36.0 million in 2020, then soared by 38.89% to $50.0 million in 2022, then plummeted by 64.0% to $18.0 million in 2023, then crashed by 44.44% to $10.0 million in 2024.
- Per Business Quant database, its latest 3 readings for R&D In Process were $10.0 million in Q1 2024, $18.0 million in Q4 2023, and $5.0 million in Q3 2023.